Deal-Making

Eli Lilly on R&D: Two thirds internal, one third external

CFO Josh Smiley says Eli Lilly is looking to source around a third of its pipeline from outside its organization. Speaking at the Goldman Sachs 40th Annual Global Healthcare Conference, Josh Smiley, chief financial officer at Eli Lilly, said his firm’s pipeline is comprised of around two thirds internal molecules and one third external. “When we look historically, we’ve done a good job in late phase of partnering and bringing in assets in earlier phases of development, getting to about…

Biotech money: Global funding down despite spate of IPOs

A decline in venture capital (VC) funding has been offset by a flood of IPOs with growth coming from non-US biotechs, according to a Jefferies analyst. For April and May 2019, biotech funding has declined 6.5% year-on-year to $9.3 billion (€8.3 billion) according to Jefferies analyst David Windley. This, he said in a note, is due to a 46% drop in VC funding as the private market continues to be less kind to biotech over the past few periods. “Both…

Celgene pays BeiGene $150m as it hands back anti-PD-1 rights

Ahead of its acquisition by Bristol-Myers Squibb, Celgene has agreed to hand back the development and commercialization rights of solid tumor candidate tislelizumab to Chinese drugmaker BeiGene. In August 2017, BeiGene inked a deal saw it acquire Celgene’s commercial operations and portfolio assets in China while handing over the exclusive rights to develop and commercialize its investigational anti-PD1 antibody, BGB-A317 (tislelizumab) for solid tumors outside of the region. But in a report filed with the SEC yesterday, BeiGene said the…

Alpine inks iPSCs vision lost therapy deal with Allele

In collaboration with Alpine BioTherapeutics Corporation, Allele Biotechnology and Pharmaceuticals will make therapies for retinal diseases based on induced pluripotent stem cells (iPSCs) The deal, financials of which have not been divulged, sees the two firms enter into a research agreement for developing iPSC-derived cell therapy for treating diseases including blindness caused by Retinitis Pigmentosa, Stargardt disease, and dry AMD. Alpine, which has a patented stem cell differentiation technique used to generate human retinal stem cells from pluripotent stem cells,…

Amgen: ‘We’ve shaved 3 years off development but can do better’

Amgen says it hopes to rapidly develop new medicines from a collaboration with Intermountain Health as its EVP of R&D discusses changing timelines. Wholly-owned Amgen subsidiary deCODE genetics will have access to the genomes of 500,000 Utah-based participants from a study carried out by not-for-profit healthcare provider Intermountain Healthcare. Amgen hopes to use this data to uncover new insights into specific diseases and develop new medicines that reach the right disease targets. Speaking at the Goldman Sachs 40th Annual Global…

Servier selects Yposkesi for viral vector supply

The deal brings Servier access to CDMO Yposkesi’ lentiviral vector production for its Phase I allogeneic CAR-T candidate UCART19. Servier has chosen contract development manufacturing and organization (CDMO) Yposkesi to provide the lentiviral vectors for its candidate UCART19, an off-the-shelf chimeric antigen receptor (CAR) T-cell in trials for haematological malignancies. According to the firm, its selection of fellow French CDMO came “after testing lentiviral vectors from several competitors and comparing the costs,” though financial and timelines details have not been…

Merck in $773m deal to add preclinical MAb firm Tilos

Merck & Co. has reached an agreement to acquire Tilos Therapeutics, a developer of monoclonal antibodies targeting the latent TGFβ complex. The deal will see biopharma firm Merck acquire private Massachusetts-based biotech Tilos Therapeutics for up to $773 million (€683 million), including an undisclosed upfront payment and milestones. Dean Li, senior vice president, discovery and translational medicine, Merck Research Laboratories, said in a statement the deal is evidence of the firm’s continued efforts to enhance its pipeline. “Tilos has developed…

Rexgenero adds CMO to speed up cell therapy trials

Regenerative medicine firm has contracted the German Red Cross Blood Donor Service to expand production of its autologous bone marrow-based cell therapy REX-001. London, UK-headquartered firm Rexgenero’s lead product is REX-001 is in two Phase III trials both of which are in diabetes patients. The firm manufactures the autologous cell therapy from its production site in Seville, Spain, added through its incorporation of Spanish subsidiary Rexgenero Biosciences S.L in 2015. But to increase production and expedite clinical trials, the firm has…

PE to boost Vibalogics’ viral vector capabilities

Private equity firm Ampersand Capital Partners has bought CDMO Vibalogics and intends to expand its capabilities to service the demand for gene therapy services. The price of the German contract development and manufacturing organization (CDMO) has not been disclosed, but Ampersand’s acquisition will help widen Vibalogics’ global reach on the back of increased demand for viral vector and gene therapy services. “Vibalogics can now strengthen and expand the position in both of its home markets, the USA and Europe, as…

Affibody contracts 3P for psoriasis protein scale-up

Contract development and manufacturing organization (CDMO) 3P Biopharmaceuticals will scale-up the manufacture of Affibody’s candidate ABY-035 for psoriasis. Swedish biopharma firm Affibody has been working with 3P since 2017 and has now secured the CDMO to transfer and scale-up the process developed prior to execution of the first GMP manufacturing batches for its candidate ABY-035. 3P will also carry out process characterization and validation ahead of commercial manufacture. “Currently the collaboration is based on GMP manufacturing for Ph II clinical…